

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/14560104>

Factor XIIIa-Catalyzed Cross-Linking of Recombinant α C Fragments of Human Fibrinogen †

ARTICLE *in* BIOCHEMISTRY · JUNE 1996

Impact Factor: 3.02 · DOI: 10.1021/bi952294k · Source: PubMed

CITATIONS

49

READS

11

4 AUTHORS, INCLUDING:



Yury V Matsuka

Pfizer Inc.

31 PUBLICATIONS 707 CITATIONS

SEE PROFILE



Leonid Medved

University of Maryland, Baltimore

118 PUBLICATIONS 3,029 CITATIONS

SEE PROFILE

Factor XIIIa-Catalyzed Cross-Linking of Recombinant α C Fragments of Human Fibrinogen[†]

Yury V. Matsuka, Leonid V. Medved, Mary M. Migliorini, and Kenneth C. Ingham*

J. Holland Laboratory, American Red Cross, Rockville, Maryland 20855

Received September 26, 1995; Revised Manuscript Received February 14, 1996[®]

ABSTRACT: Direct measurements of the structure and function of the COOH-terminal portion of the A α chain (residues 220–610) of human fibrinogen have been hampered by the difficulty of isolating intact fragments derived from this protease-sensitive region. Here, we overcame this problem by expressing two fragments, α C45K (A α 221–610) and a truncated version of it, α C30K (A α 368–610), in *Escherichia coli*. Both proteins were purified to homogeneous state, and their integrity was confirmed at protein level by sequencing. Upon treatment with factor XIIIa, the α C45K fragment but not the α C30K fragment formed polymers similar to those derived from fibrin clots. Sequence analysis of cross-linked α C45K polymers revealed involvement in the cross-linking reaction of at least three Gln residues (221, 237, 328) in the NH₂-terminal region of the fragment and four Lys residues (539, 556, 580, 601) located in the COOH-terminal part of the molecule. In addition, a fraction of α C45K fragment was found in an intramolecular cross-linked form, suggesting a high level of flexibility of its polypeptide chain and consistent with the location of its donor and acceptor residues in clusters near the ends of the molecule. The α C30K fragment, lacking the NH₂-terminal Gln residues, was not able to form polymers or internally cross-linked monomers. Thus, the C-terminal part of the A α chain comprises an autonomous, functionally active, and flexible region that plays a key role in α polymer formation and stabilization of fibrin clots by factor XIIIa.

Fibrinogen is a multidomain protein involved in blood coagulation, fibrinolysis, and other important aspects of hemostasis. It consists of three pair of nonidentical polypeptide chains, A α , B β , and γ , forming two identical subunits. Both the subunits and the chains are linked together by disulfide bonds to form a symmetrical trinodular structure (Doolittle, 1973, 1984, 1994). Each subunit comprises a number of structural and functional domains which determine the multifunctional character of this complicated molecule. Among them are the α C domains formed by the C-terminal two-thirds of each A α chain which are situated on the surface of the molecule and are involved in fibrin assembly and other processes (Mosesson et al., 1967; Medved et al., 1985). Their importance is evident from the fact that congenital defects in this region including single amino acid substitutions in fibrinogens Caracas II and Dusart (Maekawa et al., 1991; Koopman et al., 1993) or deletion of the A α 461–610 region in fibrinogen Marburg (Koopman et al., 1992) are associated with a family history of recurrent thrombosis. These fibrinogens exhibited abnormalities in polymerization and defective *in vivo* thrombolysis (Maekawa et al., 1991; Soria et al., 1983). The latter was connected with the importance of α C domains for enhancing the activation of plasminogen by tPA on the fibrin surface (Lijnen et al., 1984). The α C domains are also known to interact with thrombospondin (Tuszynski et al., 1985) and integrin-type platelet and endothelial cell receptors (Cheresh et al., 1989). In addition, these regions control activation of factor XIII (Credo et al.,

1981) and serve subsequently as its substrate, becoming cross-linked to each other and to fibronectin, α_2 -antiplasmin, thrombospondin, and von Willebrand factor (Mosher, 1976; Sakata & Aoki, 1980, 1982; Hada et al., 1982; Bale et al., 1985).

Although the importance of the α C domains is well established, not much is known about the mechanism of α polymer formation and its structure. It is also not known whether fXIIIa-catalyzed α polymer formation requires the presence of the rest of the fibrin(ogen) molecule or if α C domains could act as independent units. Very limited information is available about the number and exact location of reactive Lys residues participating in fXIIIa-catalyzed cross-linking. The fact that the COOH-terminal portions of A α chains are easily degraded by proteases (Kirschbaum & Budzynski, 1990) was a major obstacle for preparation and investigation of this very important fragment of fibrinogen. Thus, most of what we know about structure and functions of α C domains has been deduced by comparing the behavior of intact fibrin(ogen) with proteolytic derivatives lacking this portion of the A α chains (X fragments). In the present study, we overcame this problem by expressing in *Escherichia coli* two recombinant fragments from the C-terminal portion of human fibrinogen A α chain, the α C45K fragment (Gln²²¹ through Val⁶¹⁰) and its truncated version, α C30K fragment (His³⁶⁸ through Val⁶¹⁰). We have shown that α C45K but not α C30K could be effectively cross-linked by factor XIIIa with formation of polymers. Upon treatment of α C45K with fXIIIa, a significant fraction was found to be internally cross-linked. Direct analysis of fXIIIa-stabilized α C45K polymers revealed the involvement at least three Gln residues (221, 237, and 328) and four Lys residues (539, 556, 580, and 601) in the cross-linking reaction.

[†] Supported by U.S. National Institutes of Health Grant HL21791.

* To whom correspondence should be addressed at Holland Laboratory, 15601 Crabbs Branch Way, Rockville, MD 20855. Phone: (301) 738-0731. Fax: (301) 738-0794.




FIGURE 1: (Top) Schematic representation of the recombinant α C fragments and the location of Gln and Lys residues within them. The bold line depicts the single disulfide bond. Gln residues are indicated by dark arrows and Lys residues by open diamonds. (Bottom) SDS-PAGE (8–25% gel) of the expressed fragments α C30K (lanes 2 and 3) and α C45K (lanes 4 and 5) in nonreduced (lanes 2 and 4) and reduced (lanes 3 and 5) conditions. Lanes 1 and 6 contain molecular mass standards as indicated.

MATERIALS AND METHODS

Expression of Recombinant α C Fragments. Two recombinant fragments comprising residues 221–610 (α C45K fragment) and 368–610 (α C30K fragment) of the fibrinogen A α chain (Figure 1) were produced in *E. coli* using the pET-20b expression vector (Novagen Inc.). To clone the designated regions, we designed polymerase chain reaction (PCR) primers shown in detail in Table 1. The forward and reverse primers contained 21 and 20 bases, respectively, corresponding to the 5'- and 3'-terminal sequences of the desired coding segment. The forward primer incorporated the *Nde*I restriction site immediately before the coding region; the final three bases of the *Nde*I site, ATG, code for the fMet initiation residue. Because of the difficulties with direct cloning of PCR products into the pET-20b vector using *Nde*I–*Hind*III sites, we added a *Bam*HI site immediately before the *Nde*I site, which allowed the corresponding cDNA segment to be cloned into the pUC19 plasmid for amplification. The reverse primers included a TGA stop codon immediately after the coding segment, followed by a *Hind*III site. Not shown in Table 1 is the presence of six additional bases at the free 5' or 3' ends of each restriction site to facilitate binding of the restriction enzymes.

The specific cDNA fragments were generated by PCR using *Pfu* DNA polymerase (Stratagene) and a template consisting of full-length cDNA encoding the human fibrinogen A α chain kindly provided by Dr. S. Lord (Binnie et al., 1993). The reaction was cycled 15 times with denaturation at 94 °C, annealing at 50 °C, and extension at 72 °C. The amplified cDNA fragments were purified by electrophoresis in agarose gel, digested with *Bam*HI–*Hind*III restriction enzymes and ligated into the pUC19 vector. After *in vivo* amplification, the resultant plasmids were digested with *Nde*I and *Hind*III, and the 1.17- and 0.73-kilobase pair fragments were purified by agarose gel electrophoresis. These cDNA fragments were ligated into the pET-20b expression vector.

Table 1: Definition of Primers used in This Study

α C45K (Gln 221–Val 610) ^a	Fwd: GG ATC CAT ATG CAG CTT CAG AAG GTA CCC CCA Nde I
	Bam HI
	Rev compl: AAG CTT TCA GAC AGG GCG AGA TTT AGC AT Hind III
α C30K (His 368–Val 610) ^b	Fwd: GG ATC CAT ATG CAC TCT GAA TCT GGA AGT TTT Nde I
	Bam HI
	Rev compl: AAG CTT TCA GAC AGG GCG AGA TTT AGC AT Hind III

^a Forward (Fwd) and reverse complement (Rev compl) DNA sequences are indicated. ^b Both expressed fragments contain an extra NH₂-terminal fMet residue (see text).

The resulting plasmids were used for transformation of DH5 α and then BL21 *E. coli* host cells. Both cDNA fragments were sequenced in both directions to confirm the integrity of the entire coding sequence. For expression of the α C fragments, BL21 cells were grown at 37 °C in Luria broth medium containing ampicillin (50 μ g/mL). Overnight cultures were diluted 1:100 with fresh Luria broth medium, grown for 2 h at 37 °C (mid-log phase), induced with isopropyl-1-thio- β -D-galactopyranoside (0.4 mM) for 2–3 h, harvested by centrifugation, and lysed by the freeze/thaw method.

Purification of the Recombinant Fragments. The α C45K fragment was purified from the insoluble pellet of the bacterial lysate. The pellet was washed three times with TBS, pH 7.4, containing 5 mM EDTA and 0.5% Triton X-100, resulting in significant purification from *E. coli* membrane proteins. The pellet was then solubilized at room temperature during 20 min in TBS, pH 7.4, containing 8 M urea. Residual insoluble material was removed by centrifugation, and the soluble protein was further purified and the urea removed by size exclusion chromatography on a column of Superdex 75 (Pharmacia) equilibrated in TBS, pH 7.4.

The α C30K fragment was prepared from the soluble fraction of the bacterial lysate. After precipitation with 30% ammonium sulfate, the pellet was dissolved in 20 mM Tris, pH 8.0, containing 25 mM NaCl, and applied on a Q-Sepharose ion exchange column (Pharmacia) equilibrated with the same buffer. The material that eluted from the column at 170 mM NaCl represented mainly the α C30K fragment with variable amounts of its degradation products as revealed SDS-PAGE and NH₂-terminal sequence analysis. These were mostly removed by size exclusion chromatography on the Superdex 75 column equilibrated with TBS, pH 7.4. Both α C30K and α C45K fragments were concentrated and stored frozen at –70 °C.

Protein concentrations were determined spectrophotometrically using extinction coefficients calculated from the amino acid composition by the following equation: $E_{280,1\%} = (5690W + 1280Y + 120S - S)/0.1M$, where W, Y, and S–S represent the number of Trp and Tyr residues and disulfide bonds, respectively, and M represents molecular mass (Edelhoc, 1967; Gill & vonHippel, 1989; Pace et al., 1995). The following values of $E_{280,1\%}$ were obtained for recombinant fragments: α C45K, 11.6; and α C30K, 3.9.

Factor XIIIa Mediated Cross-Linking of α C Fragments. Cross-linking of the recombinant α C fragments was initiated by addition of 1 unit/mL of thrombin (Sigma) to a solution containing 0.6 mg/mL fragment and 30 μ g/mL recombinant factor XIII obtained from Dr. Paul Bishop of ZymoGenetics

(Bishop et al., 1990). The reaction was carried out in TBS, pH 7.4 containing 10 mM CaCl_2 for varying times at 25 °C. The incubation mixture was then transferred into a solution containing 2% SDS and 10% β -mercaptoethanol at 95 °C and analyzed by SDS-PAGE. Alternatively, the reaction mixture was fractionated on Superose 12 (Pharmacia), and the polymeric or internally cross-linked fractions were subjected to NH_2 -terminal sequencing.

Cyanogen Bromide and Enzymatic Cleavage. Approximately 0.1 mg of protein was dissolved in 0.5 mL of 70% formic acid, and 1 mg of CNBr was added to this solution. The reaction was allowed to proceed for 4 h at 37 °C in the dark. Samples were then dried down using a Savant SpeedVac concentrator, diluted to 1 mL with H_2O , and redried. The acceptor Gln and donor Lys residues involved in cross-linking were identified by isolation and sequencing of peptides from endoproteinase Lys-C or endoproteinase Glu-C (Boehringer-Mannheim) digests of the cross-linked αC45K fragment. Endoproteinase Lys-C digestion was performed in 50 mM TBS, pH 8.2, containing 5 mM EDTA, at 37 °C overnight; enzyme/substrate ratio was 1/60 (mass/mass). Glu-C digestion was performed in 50 mM NH_4HCO_3 buffer, pH 7.8, at room temperature overnight; enzyme/substrate ratio was 1/60 (mass/mass).

Peptide Separation. The digested fragments were fractionated on a RP300 Brownlee C-18 reverse-phase cartridge (30 \times 2.1 mm) using a Waters HPLC system equipped with two model 510 pumps, a 490E variable wavelength detector, and a 712 WISP autoinjector. Data were collected at 220 and 280 nm and analyzed using Maxima 820 software. The column was equilibrated in solvent A (0.1% by volume of trifluoroacetic acid in H_2O) and eluted with various gradients of solvent B (0.1% by volume of trifluoroacetic acid in acetonitrile). A linear gradient from 0–10% B over 5 min followed by 10–50% B over 50 min was used for the endoproteinase Lys-C digest. For the CNBr digests, the gradient was from 0 to 50% B over 100 min. For the separation of the endoproteinase Glu-C digests, a concave gradient from 0–10% B over 20 min followed by a linear gradient from 10–15% B over 40 min followed by 15–40% B over 40 min was used.

Sequence Analysis. NH_2 -terminal sequence analysis was performed with a Hewlett-Packard model G1000S sequenator. The NH_2 termini were determined by direct sequencing for several cycles. To determine the COOH termini, the corresponding material was digested with CNBr and separated by reverse-phase HPLC, and individual fragments were sequenced through the end. When analyzing various fractions from the proteolytic digests of cross-linked material, multiple residues were often found in each cycle indicating heterogeneity of the fractions from HPLC. Computer-assisted comparison of the residues in each cycle against the known sequence of αC45K allowed specific sequences to be identified.

RESULTS

Preparation and Characterization of Recombinant αC Fragments. The recombinant fragments, αC45K and αC30K comprising residues Gln²²¹ through Val⁶¹⁰ and His³⁶⁸ through Val⁶¹⁰, respectively, were directly produced in *E. coli* using the pET-20b expression vector. Both fragments contained one extra NH_2 -terminal fMet residue that initiated translation




FIGURE 2: Treatment of the αC45K (panel A) and αC30K (panel B) with factor XIIIa analyzed by reduced SDS-PAGE (4–15% gel). Lanes 1 contain the starting material. Lanes 2–6 represent increasing times of incubation (10, 30, 60, 120, and 360 min) with factor XIIIa as described in Materials and Methods.

(Studier et al., 1995). The αC45K fragment was found predominantly in the insoluble fraction. It was recovered after solubilization in 8 M urea. Solubility was retained after removal of urea, and size-exclusion chromatography revealed no sign of aggregation. Attempts to recover αC45K from the soluble fraction resulted in extraction of highly degraded material (not shown). αC30K was purified intact from the soluble fraction. The final yield of purified fragments varied between 4 and 7 mg/L of bacterial culture.

The homogeneity of the fragments was checked by SDS-PAGE. Both exhibited a major band whose mobility was slightly decreased upon reduction indicating that the single disulfide bond was intact in both recombinant fragments (Figure 1). Several minor bands with higher mobility were sometimes observed suggesting impurities or proteolytic degradation of the fragments upon preparation. However, both fragments consistently displayed a single N-terminal sequence starting at Gln²²¹ for αC45K and His³⁶⁸ for αC30K , both preceded by variable yields of Met. This suggests that the minor bands represent the same fragments with partially degraded COOH termini. To check this suggestion, a 27-kDa contaminant of αC30K (see Figure 2B) was isolated during further purification of the αC30K fragment by size exclusion chromatography, and its cyanogen bromide digest was compared with that of αC30K by reverse-phase HPLC (not shown). The digest of the αC30K fragment exhibited an extra peak that was missing in the digest of the 27-kDa fragment. The material from this peak was sequenced through the end and identified as the complete COOH-terminal CNBr fragment of the A α chain. Sequence analysis of a total CNBr digest of αC45K showed the presence of all five expected CNBr fragments. Thus sequence analysis clearly indicated that, after purification, the NH_2 and COOH termini in both fragments were mainly preserved and that the minor impurities revealed in some preparations by SDS-PAGE occurred due to partial degradation of their COOH termini.

Factor XIIIa Catalyzed Cross-Linking of the αC Fragments. Since the NH_2 -terminal portion of αC45K contains reactive Gln residues previously identified by Doolittle and co-workers (Cottrell et al., 1979) as well as the A α 518–584 region, where potential donor Lys residue(s) were predicted to occur (Doolittle et al., 1977), we checked if it could be cross-linked by factor XIIIa into polymeric structures similarly to those observed in cross-linked fibrin. Upon incubation of αC45K with factor XIIIa, the major band on SDS-PAGE corresponding to the monomeric fragment was




FIGURE 3: Repetitive yields of successive residues during NH_2 -terminal sequencing of untreated αC45K (panel A), the internally cross-linked monomeric form of αC45K (panel B), and the polymeric fraction of αC45K (panel C). Numbers above panel A indicate the position of the residues in the $\text{A}\alpha$ chain sequence. An extra fMet is denoted by the asterisk.

rapidly depleted (Figure 2A). This was accompanied by the appearance of new slower mobility bands whose apparent molecular mass was consistent with the formation of dimers, trimers, tetramers, and, most prominently, large polymers which failed to enter the gel (bands b, c, d, and e, respectively). In addition, some of the material in the incubation mixture precipitated, suggesting the formation of even higher molecular mass polymers. The results clearly indicate that cross-linking of the αC45K fragment by factor XIIIa results in the rapid formation of multimers and polymers. By contrast, the αC30K fragment, when incubated with factor XIIIa under identical conditions, was unaffected (Figure 2B), consistent with what was suggested about the distribution of donors and acceptors in different parts of the fibrinogen $\text{A}\alpha$ chain (Doolittle et al., 1977, 1979).

Figure 2A also reveals that incubation with factor XIIIa results in the gradual accumulation of an additional monomeric band (band a) with higher mobility than the original αC45K fragment. One possible explanation would be proteolytic degradation of the fragment. However, the appearance of higher mobility products was observed neither with the αC30K fragment, which was incubated with factor XIIIa under identical conditions (Figure 2B), nor with a separate sample of αC45K to which only thrombin was added, omitting factor XIII (not shown). If degradation with some other protease is responsible for the increased mobility of a portion of the αC45K fragment, this degradation should involve its NH_2 -terminal part, the part missing in αC30K which does not show the effect. To check this suggestion, the fraction which exhibited higher mobility on SDS-PAGE after 360 min of cross-linking (band a, Figure 2A) was separated from soluble multimers by size exclusion chromatography and sequenced through seven cycles. The untreated fragment and the soluble multimer fraction were also sequenced for comparison. The analysis revealed the same single NH_2 -terminal sequence in all three cases indicating that the NH_2 -terminal part of αC45K is preserved during incubation with factor XIIIa. However, unlike the untreated material (Figure 3A), both band a (Figure 3B) and the multimer fraction (Figure 3C) exhibited a depressed yield of Gln²²¹ (cycle 2) compared to Gln²²³ (cycle 4). The




FIGURE 4: HPLC separation of cross-linked peptides obtained from αC45K polymers after Glu-C digestion. The numbers designate peaks that are observed in digest of the polymers but not the monomers.

depressed yield of Gln²²¹ would be expected if it were involved in cross-linking since it would not be liberated following Edman degradation. The results seem to indicate that this residue can participate in cross-linking not only intermolecularly to form αC multimers but intramolecularly to form a more compact structure which migrates faster through the gel. The intramolecular cross-linking may also occur in some of the dimers and multimers and could account for the diffuse nature of bands b, c, and d and their tendency to shift downward with increasing time of cross-linking (Figure 2A). These results suggest a high level of flexibility in the αC45K polypeptide chain which allows fXIIIa to introduce intramolecular amide bonds and increase the mobility on SDS-PAGE.

Identification of Cross-Linked Residues in αC45K Polymers. Both untreated αC45K monomers and the cross-linked polymer fractions were treated with protease Glu-C or protease Lys-C, and HPLC profiles of their digests were compared to identify the regions involved in cross-linking. An example of a Glu-C digest is provided in Figure 4 where several new peaks designated as 1, 2, 3, and 4 are visible in the HPLC profile of the cross-linked polymeric fraction but absent in that of the untreated monomeric fragment. Some of the new peaks were shown to arise merely from changes in the digestion pattern as a result of the cross-linking reaction, presumably because of changes in the steric accessibility of cleavable bonds or, in the case of Lys-C digests, failure of the enzyme to recognize a Lys residue that was cross-linked to a Gln. Other peaks represented cross-linked peptides whose retention times were increased because of the larger size. Upon sequencing, most peaks produced multiple residues in each cycle, indicating heterogeneity of the HPLC fractions or the presence of several peptides in a given cross-linked species. Comparison of the residues in each cycle against the known sequence of αC45K allowed several individual sequences to be identified. Figure 5 presents repetitive yield data for several peptides that appeared to be involved in cross-linking as evidenced by much lower than expected yields of either Gln or Lys in a given cycle. Some of the same peptides were also identified in peaks from a digest of untreated αC45K , in which case the yields of the corresponding Gln and Lys residues were




FIGURE 5: Repetitive yields of successive residues during N-terminal sequencing of peptides isolated from proteolytic digests of the polymeric fraction of cross-linked α C45K fragment of fibrinogen. Left-hand panels present data from peptides in which reactive Gln residues were identified, as indicated inside each panel. Right-hand panels correspond to peptides in which reactive Lys residues were identified. The amino acid sequence of each peptide is indicated along the ordinate of each panel.

not depressed. Thus, the panels on the left of Figure 5 identify three different Gln residues at positions 221, 237, and 328. The panels on the right identify four Lys residues at positions 539, 556, 580, and 601.

DISCUSSION

Localization of functionally important regions of fibrinogen α C domains has been hampered by the difficulty of isolating intact homogeneous fragments containing this domain, primarily because of its vulnerability to proteolysis. Previous attempts to prepare full length α C domain from bovine fibrinogen by limited proteolysis resulted in low yields of a 40-kDa α C-fragment which had heterogeneous NH_2 termini and was missing a significant portion from its C-terminus (A α 582–610) which is thought to be important for the intramolecular association of these domains in fibrinogen (Veklich et al., 1993; Gorkun et al., 1994). One goal of the present study was to express intact homogeneous recombinant α C fragments in amounts sufficient for their characterization and functional study.

Two Recombinant Fragments Were Expressed with High Yield using the pET-20b Expression Vector. These fragments were α C45K fragment including the sequence A α 221–610 and its truncated version α C30K fragment (A α 368–610). It should be noted that our first attempts to produce recombinant α C45K fragment as a fusion protein with maltose-binding protein using the pMAL-p2 expression vector failed due to extremely high degradation of the final

product (results not shown). The use of the pET-20b expression system seems to abolish that problem. We attribute this success at least partially to the strong T7 promoter in the pET expression vector and to the lack of the *Lon* and *ompT* proteases in the BL21 *E. coli* host cell strain which was used for expression of the recombinant α C fragments.

One of the major functions of the C-terminal portions of fibrin(ogen) α chain is to stabilize fibrin clots by formation of fXIIIa cross-linked polymers. Cross-linking of α chains alters the mechanical properties of the clot and enhances a clot's resistance to lysis by plasmin (Henschen & McDonagh, 1986). When recombinant α C45K fragment was incubated in the presence of fXIIIa, the formation of dimers, trimers, tetramers, and higher molecular weight polymers was observed. Such polymerization upon treatment of the α C45K fragment with fXIIIa indicates that COOH-terminal regions of fibrin(ogen) A α chains are autonomously functioning domains with a tendency to form self-associated type structures. Recently published electron microscopy data indicate that natural α C fragments of bovine fibrinogen have a tendency to self-associate (Veklich et al., 1993). Such a tendency could explain the high efficiency of α C45K cross-linking upon its treatment with fXIIIa. Factor XIIIa introduces covalent isopeptide bonds that stabilize the associated state of the protein and render it detectable by SDS-PAGE.

Treatment of the α C45K fragment with factor XIIIa resulted not only in the formation of polymers but also in a

significant fraction of an internally cross-linked monomeric derivative whose mobility on SDS-PAGE was greater than that of the starting material. Such intramolecular cross-linking occurred also with some oligomeric species, retarding their further polymerization. Intramolecular cross-linking was shown to involve at least Gln²²¹ and unidentified Lys residue(s) presumably located in the COOH-terminal portion as presented schematically in Figure 6. The possibility that other Gln residues also participate in this reaction can not be excluded and is in fact suggested by the presence of at least one additional band at a position intermediate between the starting material and the highest-mobility band (Figure 2A). This phenomenon was not detected with the truncated α C30K fragment, which also failed to show any evidence for intermolecular cross-linking.

Reactive Gln residues that can serve as substrates for factor XIIIa and other transglutaminases are often identified through their ability to incorporate low molecular weight amine donors. For example, reactive Gln at positions 237, 328, and 366 in the A α chain were identified by incorporation of labeled Lys analogues into fibrin (Cottrell et al., 1979; Fretto et al., 1978; Henshen & McDonagh, 1986). More recently, a similar approach has been used to incorporate Gln-containing peptides into several proteins (Parameswaran et al., 1990; Bendixen et al., 1993). However, the specificity of this approach may be compromised by the high (mM) concentrations of the low molecular weight probes that are used. The present study provides the first direct identification of specific Gln and Lys residues in the fibrinogen A α chain that are actually involved in protein-protein cross-linking as opposed to merely serving as substrates for the incorporation of low molecular weight probes. Two of the three identified Gln residues, 237 and 328, are the same as those previously reported to be reactive; the third at position 221 was not previously identified. The α C45K fragment contains a total of six Gln residues, five of which are located in the N-terminal 25% of the polypeptide chain (Figure 1). Three of the six were identified as reactive in our experiments. We cannot exclude the possible involvement of additional Gln(s), e.g., Gln³⁶⁶ (Cottrell et al., 1979), since we did not sequence every HPLC peak. However, the fact that α C30K, for which Gln⁵⁶³ is the only one, did not undergo cross-linking suggests that Gln⁵⁶³ is not reactive toward factor XIIIa.

The involvement of Lys residues in the C-terminal stretch between residues 518 and 584 was expected on the basis of the suggestion by Doolittle et al. (1977), who identified this peptide (whose only Gln is no. 563) in complex with another in the CNBr digest of fully cross-linked fibrin. Three of the Lys residues shown here to be involved in cross-linking of α C polymers, residues 539, 556, and 580, are located in this region. In addition Lys⁶⁰¹ situated beyond this region was also involved in cross-linking. Again, the possible involvement of additional Lys residues such as Lys⁵⁰⁸ (Corcoran et al., 1980) cannot be excluded since not all HPLC fractions were analyzed. Nor can it be certain that all of the residues that participate in cross-linking of the α C45K fragment would also participate in the cross-linking of intact fibrin since they might be less accessible in the parent protein. This could be especially true for Gln²²¹, which is located near the NH₂ terminus of the α C45K fragment.




FIGURE 6: Schematic representation of the results of cross-linking of recombinant α C45K fragment of fibrinogen with factor XIIIa. Reactive Gln residues identified in this study are located in the N-terminal portion and Lys residues in the C-terminal portion. Intramolecular cross-linking competes with intermolecular cross-linking and also serves to impede the growth of polymers.

We were unable from our data to make a conclusion about the involvement of a specific Gln-Lys pair in the cross-linking reaction. It is likely that any one of several reactive Gln residues in the N-terminal region could be cross-linked to one of several Lys residues in the C-terminal region and *vice versa*. In any case, the availability of multiple reactive Gln and Lys residues serves to increase the probability that cross-linking occurs between α chains, consistent with the importance of this reaction for stabilizing the fibrin clot.

ACKNOWLEDGMENT

We thank Dr. Susan Lord for providing full-length cDNA of the A α chain of human fibrinogen. Thanks also to Dr. Igor Kurochkin for helpful discussions.

REFERENCES

- Bale, M. D., Westrick, L. G., & Mosher, D. F. (1985) *J. Biol. Chem.* 260, 7502–7508.
- Bendixen, E., Borth, W., & Harpel, P. C. (1993) *J. Biol. Chem.* 268, 21962–21967.
- Binnie, C. G., Hettasch, J. M., Strickland, E., & Lord, S. T. (1993) *Biochemistry* 32, 107–113.
- Bishop, P. D., Teller, D. C., Smith, R. A., Lasser, G. W., Gilbert, T., & Seale, R. L. (1990) *Biochemistry* 29, 1861–1869.
- Cheresh, D. A., Berliner, S. A., Vincente, V., & Ruggeri, Z. M. (1989) *Cell* 58, 945–953.
- Corcoran, D. H., Ferguson, E. W., Fretto, L. J., & McKee, P. A. (1980) *Thromb. Res.* 19, 883–888.
- Cottrell, B. A., Strong, D. D., Watt, K. W. K., & Doolittle, R. F. (1979) *Biochemistry* 18, 5405–5410.
- Credo, R. B., Curtis, C. G., & Lorand, L. (1981) *Biochemistry* 20, 3770–3778.
- Doolittle, R. F. (1973) *Adv. Protein Chem.* 27, 1–101.
- Doolittle, R. F. (1984) *Annu. Rev. Biochem.* 53, 195–229.
- Doolittle, R. F. (1994) in *Molecular Basis of Blood Diseases*, (Stamatoyannopoulos, G., Nienhuis, A. W., Majerus, P. W., & Varmus, H. W. B., Eds.) pp 701–723, Saunders Co., Philadelphia, PA.

- Doolittle, R. F., Cassman, K. G., Cottrell, B. A., & Friezner, S. J. (1977) *Biochemistry* 16, 1715–1719.
- Doolittle, R. F., Watt, K. W. K., Cottrell, B. A., Strong, D. D., & Riley, M. (1979) *Nature* 280, 464–468.
- Edelhoch, H. (1967) *Biochemistry* 6, 1948–1954.
- Fretto, L. J., Ferguson, E. W., Steinman, H. M., & McKee, P. A. (1978) *J. Biol. Chem.* 253, 2184–2195.
- Gorkun, O. V., Veklich, Y. I., Medved, L. V., Henschen, A. H., & Weisel, J. W. (1994) *Biochemistry* 33, 6986–6997.
- Gill, S. C., & von Hippel, P. H. (1989) *Anal. Biochem.* 182, 319–326.
- Hada, M., Kato, M., Ikematsu, S., Fujimaki, M., & Fukutake, K. (1982) *Thromb. Res.* 25, 163–168.
- Henschen, A., & McDonagh, J. (1986) in *Blood Coagulation* (Zwaal, R. F. A., & Hemker, H. C., Eds.) pp 171–241, Elsevier Science Publishers, Amsterdam.
- Kirschbaum, N. E., & Budzynski, A. Z. (1990) *J. Biol. Chem.* 265, 13669–13676.
- Koopman, J., Haverkate, F., Grimbergen, J., Egbring, R., & Lord, S. T. (1992) *Blood* 80, 1972–1979.
- Koopman, J., Haverkate, F., Grimbergen, J., Lord, S. T., Mosesson, M. W., DiOrio, J. P., Siebenlist, K. S., Legrand, C., Soria, J., Soria, C., & Caen, J. P. (1993) *J. Clin. Invest.* 91, 1637–1643.
- Lijnen, H. R., Soria, J., Soria, C., Collen, D., & Caen, J. P. (1984) *Thromb. Haemost.* 51, 108–109.
- Maekawa, H., Yamazumi, K., Muramatsu, S., Kaneko, M., Hirata, H., Takahashi, N., de Bosch, N. B., Carvajal, Z., Ojeda, A., Arocha-Pinango, C. L., & Matsuda, M. (1991) *J. Biol. Chem.* 266, 11575–11581.
- Medved, L. V., Gorkun, O. V., Manyakov, V. F., & Belitser, V. A. (1985) *FEBS Lett.* 181, 109–112.
- Mosesson, M. W., Alkjaersig, N., Sweet, B., & Sherry, S. (1967) *Biochemistry* 6, 3279–3287.
- Mosher, D. F. (1976) *J. Biol. Chem.* 251, 1639–1645.
- Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., & Gray, T. (1995) *Protein Sci.* 4, 2411–2423.
- Parameswaran, K. N., Velasco, P. T., Wilson, J., & Lorand, L. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87, 8472–8475.
- Sakata, Y., & Aoki, N. (1980) *J. Clin. Invest.* 65, 290–297.
- Sakata, Y., & Aoki, N. (1982) *J. Clin. Invest.* 69, 536–542.
- Soria, J., Soria, C., & Caen, J. P. (1983) *Br. J. Haematol.* 53, 575–586.
- Studier, F. W., Rosenberg, A. H., Dunn, J. J., & Dubendorff, J. W. (1995) *Methods Enzymol.* 185, 60–89.
- Tuszynski, G. P., Srivastava, S., Switalska, H. I., Holt, J. C., Cierniewski, C. S., & Niewiarowski, S. (1985) *J. Biol. Chem.* 260, 12240–12245.
- Veklich, Y. I., Gorkun, O. V., Medved, L. V., Nieuwenhuizen, W., & Weisel, J. W. (1993) *J. Biol. Chem.* 268, 13577–13585.

BI952294K